Intelligent Bio Solutions Inc., a Delaware-based company listed on the Nasdaq Stock Market under the symbol INBS, has reported a significant achievement in its latest Form 8-K filing with the SEC. On August 21, 2024, the company announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024. This marks a 65% increase from the previous year's count of 630, reflecting a growing demand for the company's innovative drug screening technology. The fiscal year ending June 30, 2024, saw a 26% increase in reader sales, totaling 407 units. The company's drug screening system, which provides quick and reliable results using non-invasive methods, has also seen a 20% increase in cartridge sales year-over-year. Intelligent Bio Solutions is making strides towards FDA...Show More

Intelligent Bio Solutions Inc., a Delaware-based company listed on the Nasdaq Stock Market under the symbol INBS, has reported a significant achievement in its latest Form 8-K filing with the SEC. On August 21, 2024, the company announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024. This marks a 65% increase from the previous year's count of 630, reflecting a growing demand for the company's innovative drug screening technology. The fiscal year ending June 30, 2024, saw a 26% increase in reader sales, totaling 407 units. The company's drug screening system, which provides quick and reliable results using non-invasive methods, has also seen a 20% increase in cartridge sales year-over-year. Intelligent Bio Solutions is making strides towards FDA clearance for its cartridges, which are considered a Class II device requiring a pre-market notification 510(k). The company's President and CEO, Harry Simeonidis, expressed confidence in the continued growth and demand for their non-invasive drug screening system. The company's forward-looking statements indicate plans for further expansion and commercialization of its drug and diagnostic tests.